WALLACH et al. V. SMITH - Page 14


               Interference No. 103,854                                                                                              


              specification helps to resolve the issue of what the inventors intended by the meaning of the                          
              phrase “encapsulated in a liposome.”                                                                                   
                     In turning to the prosecution history, however, we find what appears to be the origin of                        
              the problematic claim language.  Claims 4 and 26 of the original Wallach specification were                            
              directed to a multimer comprising a liposome.  The examiner rejected these claims as being                             
              indefinite under 35 U.S.C. § 112, second paragraph.  Paper No. 9, p. 5.  In so doing, the                              
              examiner stated that she “interpreted these claims to mean the encapsulation of TNF-R                                  
              multimers in liposomes for examining  purposes” [emphasis added].  Id.  In addition, the                               
              examiner rejected the claims over two references, one of which (Allen, U.S. Patent                                     
              4,837,028, issued Jun. 6, 1989) was said to describe the encapsulation of a pharmaceutical                             
              agent within a liposome in order to preserve its half-life in the blood stream and to reduce                           
              any toxic side effects [emphases added].  Id., p. 7.  The examiner concluded that “it would                            
              have been obvious to one of ordinary skill in the art that TNF-BP multimers could be placed                            
              within liposomes to increase their half-life and reduce their possible side effects because the                        
              primary references teach that TNF-BPs bind TNF to prevent its activity while the remaining                             
              references teaches [sic, teach] the use of liposomes to administer agents such as TNF to                               
              retain activity, increase half life, and reduce side effects” [emphasis added].  Id.  In response                      
              to these rejections, Wallach did not object to the examiner’s statements.  Rather, they                                
              amended the claims to include the phrase “encapsulated in a liposome.”11  Paper Nos. 10                                
              and 13.                                                                                                                
                     Thus, from the prosecution history, we find that the phrase “encapsulated in a                                  
              liposome” was used by the examiner in concordance with the ordinary and accustomed                                     

                       11 Wallach deleted claim 26 by amendment in Paper No. 13, p. 2.  The                                          
               numbering of claim 4 was changed to claim 7 when the Wallach application issued as a                                  
               patent.                                                                                                               
                                                                  14                                                                 


Page:  Previous  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  Next 

Last modified: November 3, 2007